- Conditions
- Hypertension
- Interventions
- ADX415, Placebo
- Drug
- Lead sponsor
- Addrenex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Austin, Texas • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,765
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- VI-0521, Placebo matched phentermine/topiramate
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 5
- States / cities
- San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
- Conditions
- Vitamin D Deficiency
- Interventions
- High Dose Vitamin D3, Low Dose Vitamin D3, Placebo
- Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Up to 75 Years · Female only
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- Placebo, RO7017773
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 15 Years to 45 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more
- Conditions
- Major Depressive Disorder
- Interventions
- Levomilnacipran ER, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 33 more
- Conditions
- HIV Infection
- Interventions
- Griffithsin Gel, Placebo Gel
- Drug
- Lead sponsor
- Population Council
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Cystic Fibrosis
- Interventions
- Inhaled AR-501, Inhaled Placebo
- Drug
- Lead sponsor
- Aridis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
- Conditions
- Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
- Interventions
- Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Sickle Cell Disease
- Interventions
- Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER, High Dose Rifaximin DER, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Orange, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Chronic Hepatitis B Virus Infection, Hepatitis B
- Interventions
- Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
- Conditions
- Asthma
- Interventions
- FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
- Conditions
- Cognitive Deficits in Schizophrenia
- Interventions
- ABT-288 Low Dose, Placebo, ABT-288 High Dose
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Anaheim, California • Garden Grove, California • National City, California + 20 more
- Conditions
- Bacterial Infections
- Interventions
- VNRX-5133, VNRX-5022, Metronidazole, Placebo
- Drug
- Lead sponsor
- Venatorx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Lung Injury, Acute
- Interventions
- Dose 1 GSK2586881, Dose 2 GSK2586881, Dose 3 GSK2586881, Dose 4 GSK2586881, Placebo (saline)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Sacramento, California • Chicago, Illinois • Springfield, Massachusetts + 9 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate, Placebo
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Placebo, ECC4703, ECC0509
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 70
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 59 more
- Conditions
- Polycystic Kidney Disease
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Bone Loss
- Interventions
- Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Winston-Salem, North Carolina
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis
- Interventions
- Norketotifen, Placebo
- Drug
- Lead sponsor
- Emergo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Resistance Exercise Performance, Cognitive Function, Anaerobic Performance, Dietary Supplementation Athletic Performance
- Interventions
- Low-dose Blackcurrant Supplement, High-dose Blackcurrant Supplement, Maltodextrin (Placebo)
- Dietary Supplement
- Lead sponsor
- Jacksonville State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Jacksonville, Alabama
- Conditions
- Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 30 Weeks
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Pulmonary Embolism, Thrombotic Disease
- Interventions
- DS-1040b, Placebo, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Interventions
- BAY1213790 (Osocimab), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 704 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 26
- States / cities
- Azusa, California • Brawley, California • Encino, California + 21 more
- Conditions
- Drug-induced Tardive Dyskinesia
- Interventions
- SNC-102, Placebo
- Drug
- Lead sponsor
- Synchroneuron Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California